U.S. markets close in 3 hours 47 minutes

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7800-0.0300 (-1.07%)
As of 12:09PM EDT. Market open.

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
http://www.arbutusbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. William H. CollierPres, CEO & Director972.32kN/A1960
Dr. Michael J. SofiaChief Scientific Officer637.75kN/A1958
Mr. Michael J. McElhaughChief Bus. Officer603.42kN/A1974
Mr. David C. HastingsCFO & Chief Accounting OfficerN/AN/A1961
Pam MurphyInvestor Relations ConsultantN/AN/AN/A
Dr. Elizabeth HowardExec. VP, Gen. Counsel, Chief Compliance Officer & Sec.N/AN/A1954
Dr. Gaston Picchio Ph.D.Chief Devel. OfficerN/AN/A1963
Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.CSec.N/AN/A1951
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Corporate Governance

Arbutus Biopharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.